Charles River Q1 revenue down 2.7% to $984.2M; raises FY2025 guidance

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

2025-Q1 EPS reported $0.50 revenue$984,168,000

GAAP EPS $0.50 vs $1.30 YoY; Non-GAAP EPS $2.34 vs $2.27, up 3.1%.
Revenue decline across all segments: RMS -3.5%, DSA -2.1%, Manufacturing -3.6%.
DSA net bookings reached highest level in two years, signaling demand stabilization.
Raised FY2025 Non-GAAP EPS guidance to $9.30-$9.80 from $9.10-$9.60; organic revenue growth range narrowed.
Repurchased $350M of common stock in Q1; $549.3M remaining on $1B authorization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.